Abstract P4-21-39: Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Michelangelo study

Lorenzo Gianni, G. Viale(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Mauro Mansutti(Ospedale Santa Maria della Misericordia di Udine), Milvia Zambetti(Hospital Clínico Universitario de Valencia), Giancarlo Bisagni, Marco Colleoni(European Institute of Oncology), Pinuccia Valagussa(Fondazione Michelangelo), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Lucia Del Mastro(Ospedale Policlinico San Martino), Raffaella De Fato(Fondazione Michelangelo), Claudio Zamagni(Policlinico S.Orsola-Malpighi)
Cancer Research
February 15, 2017
10.1158/1538-7445.sabcs16-p4-21-39
Cited by 5

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k